Cargando…

Nomograms Based on the Albumin/Neutrophil-to-Lymphocyte Ratio Score for Predicting Coronary Artery Disease or Subclinical Coronary Artery Disease

PURPOSE: To develop and validate two nomograms incorporating the albumin/neutrophil-to-lymphocyte ratio score (ANS) for predicting the risk of coronary artery disease (CAD) or subclinical CAD. PATIENTS AND METHODS: Four hundred fifty patients with suspected CAD who underwent coronary computed tomogr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Chen, Fan, Wenjun, Zhang, Ying, Liu, Yixiang, Ding, Zhenjiang, Si, Yueqiao, Liu, Jingyi, Sun, Lixian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844825/
https://www.ncbi.nlm.nih.gov/pubmed/36660374
http://dx.doi.org/10.2147/JIR.S392482
Descripción
Sumario:PURPOSE: To develop and validate two nomograms incorporating the albumin/neutrophil-to-lymphocyte ratio score (ANS) for predicting the risk of coronary artery disease (CAD) or subclinical CAD. PATIENTS AND METHODS: Four hundred fifty patients with suspected CAD who underwent coronary computed tomographic angiography were consecutively enrolled between September 2015 and June 2017. Nomograms were established based on independent predictors of CAD or subclinical CAD. RESULTS: In total, 437 patients with suspected CAD who underwent coronary computed tomographic angiography were included. Male sex, age ≥65 years, smoking, hypertension, diabetes, dyslipidemia, ischemic stroke, and ANS were independent predictors of CAD and subclinical CAD. The areas under the curve of each nomogram were 0.799 (95% CI: 0.752–0.846) and 0.809 (95% CI: 0.762–0.856), respectively. The calibration curve and decision curve analysis showed good performance for the diagnostic nomograms. The prediction of CAD or subclinical CAD by the ANS was not modified by the independent predictors (all, p for interaction >0.05). CONCLUSION: Our ANS-based nomograms can provide accurate and individualized risk predictions for patients with suspected CAD or subclinical CAD.